0
0
Calcium supplements do not raise dementia risk in older women, according to a major new long-term study that dispels long-held concerns about cognitive harm and supports the safety of calcium supplementation for bone health in this population. This research provides reassuring evidence that calcium supplementation, frequently used to prevent osteoporosis and fractures, does not increase risk of dementia-related events even after extended follow-up of 14.5 years. The findings are important for public health messaging and clinical practice, given the high prevalence of calcium supplement use among older adults.
Key Study Findings
A randomized, double-blind, placebo-controlled trial conducted by researchers from Edith Cowan University, Curtin University, and the University of Western Australia examined 1,460 women aged 70 and older. Participants received either 1200 mg of elemental calcium daily or a placebo for five years. They were then followed through health records for a median of 14.5 years to assess hospitalizations or deaths related to dementia.
The study found no increase in dementia risk among women taking calcium supplements compared to those on placebo. Approximately 18% of participants experienced dementia-related events, but the rates were similar between both groups. The hazard ratio for all-cause dementia was 0.90, indicating a slight but non-significant decreased risk for the calcium group. Dementia-related hospitalizations and deaths also showed no significant differences between groups after adjusting for lifestyle factors, dietary calcium intake, and genetic risk.
Additional subgroup analyses found no increased risk even among women with atherosclerotic vascular disease or high baseline dementia risk. The authors concluded that calcium supplementation for five years did not elevate dementia risk in older women, effectively debunking prior observational studies that suggested a link.
Expert Perspectives
Ms. Negar Ghasemifard, PhD student at Edith Cowan University and lead author, explained: “Previous research raised concerns around potential cognitive impacts of calcium supplements. Our rigorous trial-based analysis provides reassurance to patients and clinicians about the cognitive safety of calcium monotherapy in older women.”
Dr. Marc Sim, senior research fellow involved in the study, emphasized the study’s strengths: “Unlike earlier observational studies, our randomized trial reduces the chance of confounding factors, supporting the conclusion that calcium supplements pose no long-term dementia risk.”
However, researchers caution that these results apply specifically to older women on calcium monotherapy. They do not extend to younger people, men, or combined calcium and vitamin D supplementation regimens, which remain widely used and clinically appropriate.
Context and Background
Osteoporosis affects around 20% of women over 70, and calcium supplementation is commonly recommended to maintain bone health and prevent fractures. Calcium deficiency contributes to bone weakening, but decisively linking supplementation with cognitive outcomes has been difficult.
Earlier observational studies suggested increased dementia risk in calcium supplement users, especially those with cerebrovascular disease or prior stroke, but such findings were limited by small sample sizes and potential confounding. One 2016 Swedish cohort study reported a higher odds of dementia with calcium supplementation in women with cerebrovascular conditions. However, the new randomized trial offers stronger evidence by controlling for multiple biases and extended follow-up.
Implications for Public Health
The new evidence supports continued use of calcium supplements for fracture prevention in older women without fear of increasing dementia risk. It also counters misinformation that may deter patients from beneficial bone health interventions. Healthcare providers should continue to counsel patients on appropriate calcium use, monitor for adverse effects like constipation or kidney stones, and consider drug interactions.
The findings balance the benefits of supplementation against unsubstantiated concerns about cognitive harm, emphasizing personalized care decisions based on individual patient profiles.
Limitations and Balanced View
While robust, the study’s limitations include its focus on community-dwelling older women only and exclusion of vitamin D co-supplementation effects. Further research is needed to explore calcium’s cognitive impact in men, younger populations, and combined supplement regimens. Observational signals of risk in cerebrovascular patients may still warrant cautious monitoring.
The study underscores the importance of randomized controlled trials for clarifying supplement safety, as observational data can be confounded by underlying health conditions and behaviors.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
